Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : Gets CHMP Positive Opinion for Covid-19 Treatments

03/05/2021 | 12:09pm EDT

By Colin Kellaher

Eli Lilly & Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive scientific opinion for the company's antibody-based Covid-19 drugs aimed at helping people at high risk of severe disease avoid hospitalization.

The Indianapolis drugmaker said the opinion covers its monoclonal antibody bamlanivimab alone and in combination with one named etesevimab for the treatment of confirmed Covid-19 in patients ages 12 years and older who don't need supplemental oxygen and are at high risk of progressing to severe Covid-19.

Monoclonal antibodies are engineered proteins that mimic the immune system's ability to fight off viruses.

Eli Lilly said European Union member states can consider the opinion when making decisions on use of the therapies at a national level before a formal marketing authorization is issued by the European Commission.

The company noted that other countries look to CHMP advice to support their own reviews.

"We hope this opinion will accelerate those reviews and authorizations, particularly in low- and middle-income countries, where Lilly is prepared to provide doses at greatly reduced costs or free of charge," the company said.

The Food and Drug Administration has granted emergency-use authorization to bamlanivimab and the bamlanivimab/etesevimab combination.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

03-05-21 1209ET

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -1.57% 188.04 Delayed Quote.13.10%
S&P GSCI GOLD INDEX -0.50% 1037.8437 Delayed Quote.-5.38%
All news about ELI LILLY AND COMPANY
09:15aELI LILLY AND COMPANY  : quaterly earnings release
04/21ELI LILLY AND  : Japan health ministry panel OKs 3rd COVID-19 treatment drug
AQ
04/20ELI LILLY AND  : Reports Positive Results From Phase 3 Trial Of Potential Alopec..
MT
04/20ELI LILLY, INCYTE  : Baricitinib Improves Hair Regrowth in Alopecia Areata
DJ
04/20ELI LILLY AND  : Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alope..
PR
04/19ELI LILLY AND  : Lilly requests revocation of emergency use authorization for ba..
AQ
04/19ELI LILLY AND  : FDA Grants Eli Lilly's Request to Revoke EUA for Standalone Bam..
MT
04/16Lilly Ends U.S. Use of Single Covid-19 Antibody Drug Alone -- Update
DJ
04/16ELI LILLY AND  : Asks FDA to Revoke Bamlanivimab EUA as Combination With Etesevi..
MT
04/16SECTOR UPDATE : Health Care Stocks Trade Higher Premarket Friday
MT
More news
Financials (USD)
Sales 2021 27 845 M - -
Net income 2021 7 168 M - -
Net Debt 2021 11 336 M - -
P/E ratio 2021 24,3x
Yield 2021 1,75%
Capitalization 174 B 174 B -
EV / Sales 2021 6,64x
EV / Sales 2022 6,52x
Nbr of Employees 35 000
Free-Float 99,5%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 215,78 $
Last Close Price 190,95 $
Spread / Highest target 33,5%
Spread / Average Target 13,0%
Spread / Lowest Target -11,0%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Senior VP, Chief Information & Digital Officer
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY13.10%173 263
JOHNSON & JOHNSON5.85%438 583
ROCHE HOLDING AG2.64%298 619
PFIZER, INC.6.03%217 716
NOVARTIS AG-2.89%199 956
MERCK & CO., INC.-3.14%198 884